Application of GGPPS genes in preparation of medicines for treating non-alcoholic fatty liver disease

Abstract

The invention provides an application of GGPPS serving as a target for treating non-alcoholic fatty liver disease. A GGPPS antagonist disclosed by the invention can reduce genetic expression related to lipid accumulation of the liver. The liver-specific knockout GGPPS disclosed by the invention is capable of retarding the lipid accumulation and degeneration of the liver, reducing the level of aspartate transaminase (AST) and alanine aminotransferase (ALT) and protecting the liver functions.

Description

technical field [0001] The invention relates to the use of GGPPS gene in the preparation of medicine for treating nonalcoholic fatty liver. Liver-specific GGPPS knockout and GGPPS antagonist can reduce liver lipid accumulation and have significant effect on treating nonalcoholic fatty liver. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by fatty degeneration and lipid accumulation in hepatic cells without a history of excessive alcohol consumption but with pathological changes similar to alcoholic fatty liver disease (AFLD). Its disease spectrum includes four pathological stages from mild to severe: simple fatty liver, steatohepatitis (NASH), fatty liver fibrosis and fatty liver cirrhosis. In recent years, due to changes in lifestyle and dietary structure, NAFLD has attracted more and more attention along with the increase of obesity, type 2 diabetes, dyslipidemia and other metabolic related diseases....

AI Technical Summary

Problems solved by technology

Studies have reported that using GGPPS as a drug target can improve osteoblast differentiation and bone construction (Weivoda and Hohl 2011), and some studies have also demonstrated that GGPPS can be u

Images